title: Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.
abstract: Receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG) play key roles in the pathogenesis of glucocorticoid-induced osteoporosis (GIO). The aim of our study was to determine whether the cumulative glucocorticoid dose (CGCS) in children with idiopathic nephrotic syndrome (INS) has any effect on the concentration of serum RANKL and OPG and the RANKL/OPG ratio. The study population consisted of 90 children with INS, aged 3-20 years, who were treated with GCS. These children were divided into two groups according to the CGCS: low (L)<1 g/kg body weight (BW) and high (H)>or=1 g/kg BW, respectively. The control group (C) consisted of 70 healthy children. RANKL concentration was observed to be significantly higher and OPG significantly lower in INS children than in the reference group: 0.21 (range 0.01-1.36) versus 0.15 (0-1.42) pmol/l (p<0.05), respectively, and 3.76 (1.01-7.25) versus 3.92 (2.39-10.23) pmol/l (p<0.05), respectively. The RANKL/OPG ratio was significantly higher in INS children (p<0.01). The concentration of RANKL, similar to the RANKL/OPG ratio, was significantly higher in Group H children than in Group L children: 0.46 (0.02-1.36 ) versus 0.19 (0.01-1.25) (p<0.01) and 0.14 (0.01-0.71) versus 0.05 (0.002-0.37) (p<0.01), respectively. The concentration of OPG was similar in both groups. There was a positive correlation between CGCS and the concentration of sRANKL as well as the RANKL/OPG ratio (in both cases r=0.33, p<0.05). Based on these results, we suggest that long-term exposure to GCS results in a dose-dependent increase in serum RANKL concentration and the RANKL/OPG ratio, but not in the level of serum OPG.
authors.affiliation: Department of Paediatrics and Nephrology, Medical University of Białystok, 17 Waszyngtona Street, 15-274, Białystok, Poland. annwasil@interia.pl
authors.forename: Anna
authors.initials: A
authors.lastname: Wasilewska
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Rybi-Szuminska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Zoch-Zwierz
mesh_terms: D000293:Adolescent; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D009404:Nephrotic Syndrome / Q000097:blood* / Q000188:drug therapy; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood*; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human